Cipla yesterday launched the life saving drug, Remdesivir’s generic version, Cipremi and it priced it lowest in the world at Rs.4000 per 100 mg vial. The company kept up the promise of not pricing it over Rs.5000.

The company will be supplying 80,000 vials within the first month and will be available through the government and hospitals only.

Cipla’s product is cheaper than Mylan’s – Desrem at Rs.4800/vial or Hetero Labs – Covifor for Rs.5400/vial.

Remdesivir is the only US FDA approved Emergency Use Authorisation (EUA) treatment for adult and paediatric patients hospitalised with suspected or laboratory confirmed COVID-19 infection.

The stock is in the green; from its close of Rs.634.45, the stock opened at Rs.645.20, which is its intraday high. It is currently come off the high and is trading at Rs.638 levels.